Do analysts rate MGNX or CALT?

MacroGenics presently has a consensus target price of $5.50, suggesting a potential upside of 28.21%. Given MacroGenics' stronger consensus rating and higher probable upside, equities research analysts clearly believe MacroGenics is more favorable than Calliditas Therapeutics AB (publ). Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MacroGenics 1 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.29 Calliditas Therapeutics AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Does the media favor COLL or MGNX?

In the previous week, Collegium Pharmaceutical had 1 more articles in the media than MacroGenics. MarketBeat recorded 5 mentions for Collegium Pharmaceutical and 4 mentions for MacroGenics. Collegium Pharmaceutical's average media sentiment score of 0.91 beat MacroGenics' score of 0.91 indicating that Collegium Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Collegium Pharmaceutical 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MacroGenics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to MGNX or PURR?

In the previous week, MacroGenics had 1 more articles in the media than Hyperliquid Strategies. MarketBeat recorded 4 mentions for MacroGenics and 3 mentions for Hyperliquid Strategies. MacroGenics' average media sentiment score of 0.91 beat Hyperliquid Strategies' score of 0.65 indicating that MacroGenics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MacroGenics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Hyperliquid Strategies 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, XNCR or MGNX?

MacroGenics has higher revenue and earnings than Xencor. Xencor is trading at a lower price-to-earnings ratio than MacroGenics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Xencor $125.58M 8.83 -$91.92M -$2.29 N/A MacroGenics $149.50M 1.82 -$74.62M -$1.10 N/A

Is XNCR or MGNX more profitable?

MacroGenics has a net margin of -44.79% compared to Xencor's net margin of -177.10%. Xencor's return on equity of -28.77% beat MacroGenics' return on equity. Company Net Margins Return on Equity Return on Assets Xencor -177.10% -28.77% -20.52% MacroGenics -44.79% -147.80% -28.40%

Does the media prefer XNCR or MGNX?

In the previous week, Xencor had 2 more articles in the media than MacroGenics. MarketBeat recorded 6 mentions for Xencor and 4 mentions for MacroGenics. MacroGenics' average media sentiment score of 0.91 beat Xencor's score of 0.66 indicating that MacroGenics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xencor 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MacroGenics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to MGNX or SANA?

In the previous week, MacroGenics and MacroGenics both had 4 articles in the media. MacroGenics' average media sentiment score of 0.91 beat Sana Biotechnology's score of 0.47 indicating that MacroGenics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MacroGenics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sana Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

MacroGenics (MGNX) Competitors

$4.29 -0.21 (-4.67%)

Closing price 07/14/2026 04:00 PM Eastern

Extended Trading

$4.84 +0.55 (+12.82%)

As of 05:45 AM Eastern

Compare

MGNX vs. CALT, COLL, PURR, XNCR, and SANA

Should you buy MacroGenics stock or one of its competitors? MarketBeat compares MacroGenics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with MacroGenics include Calliditas Therapeutics AB (publ) (CALT), Collegium Pharmaceutical (COLL), Hyperliquid Strategies (PURR), Xencor (XNCR), and Sana Biotechnology (SANA). These companies are all part of the "pharmaceutical products" industry.

How does MacroGenics compare to Calliditas Therapeutics AB (publ)?

MacroGenics (NASDAQ:MGNX) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, analyst recommendations, profitability and dividends.

MacroGenics has a beta of 1.18, indicating that its share price is 18% more volatile than the broader market. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, indicating that its share price is 77% more volatile than the broader market.

In the previous week, MacroGenics had 4 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 4 mentions for MacroGenics and 0 mentions for Calliditas Therapeutics AB (publ). MacroGenics' average media sentiment score of 0.91 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that MacroGenics is being referred to more favorably in the media.

Company	Overall Sentiment
MacroGenics	Positive
Calliditas Therapeutics AB (publ)	Neutral

Calliditas Therapeutics AB (publ) has a net margin of -30.18% compared to MacroGenics' net margin of -44.79%. MacroGenics' return on equity of -147.80% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MacroGenics	-44.79%	-147.80%	-28.40%
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%

96.9% of MacroGenics shares are held by institutional investors. Comparatively, 2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. 13.6% of MacroGenics shares are held by insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

MacroGenics presently has a consensus target price of $5.50, suggesting a potential upside of 28.21%. Given MacroGenics' stronger consensus rating and higher probable upside, equities research analysts clearly believe MacroGenics is more favorable than Calliditas Therapeutics AB (publ).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MacroGenics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
Calliditas Therapeutics AB (publ)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Calliditas Therapeutics AB (publ) has higher revenue and earnings than MacroGenics. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than MacroGenics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MacroGenics	$149.50M	1.82	-$74.62M	-$1.10	N/A
Calliditas Therapeutics AB (publ)	$1.60B	0.74	-$43.96M	-$1.85	N/A

Summary

MacroGenics beats Calliditas Therapeutics AB (publ) on 11 of the 16 factors compared between the two stocks.

How does MacroGenics compare to Collegium Pharmaceutical?

Collegium Pharmaceutical (NASDAQ:COLL) and MacroGenics (NASDAQ:MGNX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, dividends, valuation and earnings.

96.9% of MacroGenics shares are owned by institutional investors. 1.9% of Collegium Pharmaceutical shares are owned by insiders. Comparatively, 13.6% of MacroGenics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Collegium Pharmaceutical has a net margin of 9.41% compared to MacroGenics' net margin of -44.79%. Collegium Pharmaceutical's return on equity of 95.18% beat MacroGenics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Collegium Pharmaceutical	9.41%	95.18%	16.39%
MacroGenics	-44.79%	-147.80%	-28.40%

Collegium Pharmaceutical has a beta of 0.73, indicating that its stock price is 27% less volatile than the broader market. Comparatively, MacroGenics has a beta of 1.18, indicating that its stock price is 18% more volatile than the broader market.

Collegium Pharmaceutical currently has a consensus target price of $57.50, suggesting a potential upside of 64.19%. MacroGenics has a consensus target price of $5.50, suggesting a potential upside of 28.21%. Given Collegium Pharmaceutical's stronger consensus rating and higher probable upside, analysts plainly believe Collegium Pharmaceutical is more favorable than MacroGenics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Collegium Pharmaceutical	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	3.17
MacroGenics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

Collegium Pharmaceutical has higher revenue and earnings than MacroGenics. MacroGenics is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Collegium Pharmaceutical	$780.57M	1.45	$62.87M	$2.04	17.17
MacroGenics	$149.50M	1.82	-$74.62M	-$1.10	N/A

In the previous week, Collegium Pharmaceutical had 1 more articles in the media than MacroGenics. MarketBeat recorded 5 mentions for Collegium Pharmaceutical and 4 mentions for MacroGenics. Collegium Pharmaceutical's average media sentiment score of 0.91 beat MacroGenics' score of 0.91 indicating that Collegium Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Collegium Pharmaceutical	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MacroGenics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Collegium Pharmaceutical beats MacroGenics on 12 of the 16 factors compared between the two stocks.

How does MacroGenics compare to Hyperliquid Strategies?

MacroGenics (NASDAQ:MGNX) and Hyperliquid Strategies (NASDAQ:PURR) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, media sentiment, valuation and earnings.

In the previous week, MacroGenics had 1 more articles in the media than Hyperliquid Strategies. MarketBeat recorded 4 mentions for MacroGenics and 3 mentions for Hyperliquid Strategies. MacroGenics' average media sentiment score of 0.91 beat Hyperliquid Strategies' score of 0.65 indicating that MacroGenics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MacroGenics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Hyperliquid Strategies	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

96.9% of MacroGenics shares are owned by institutional investors. Comparatively, 9.5% of Hyperliquid Strategies shares are owned by institutional investors. 13.6% of MacroGenics shares are owned by company insiders. Comparatively, 8.5% of Hyperliquid Strategies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Hyperliquid Strategies has a net margin of 0.00% compared to MacroGenics' net margin of -44.79%. Hyperliquid Strategies' return on equity of -56.04% beat MacroGenics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MacroGenics	-44.79%	-147.80%	-28.40%
Hyperliquid Strategies	N/A	-56.04%	-52.22%

Hyperliquid Strategies has lower revenue, but higher earnings than MacroGenics. MacroGenics is trading at a lower price-to-earnings ratio than Hyperliquid Strategies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MacroGenics	$149.50M	1.82	-$74.62M	-$1.10	N/A
Hyperliquid Strategies	$1M	1,063.15	-$16.01M	-$7.37	N/A

MacroGenics presently has a consensus price target of $5.50, suggesting a potential upside of 28.21%. Hyperliquid Strategies has a consensus price target of $12.72, suggesting a potential upside of 72.78%. Given Hyperliquid Strategies' stronger consensus rating and higher probable upside, analysts clearly believe Hyperliquid Strategies is more favorable than MacroGenics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MacroGenics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
Hyperliquid Strategies	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

MacroGenics has a beta of 1.18, indicating that its stock price is 18% more volatile than the broader market. Comparatively, Hyperliquid Strategies has a beta of 1.66, indicating that its stock price is 66% more volatile than the broader market.

Summary

Hyperliquid Strategies beats MacroGenics on 8 of the 15 factors compared between the two stocks.

How does MacroGenics compare to Xencor?

Xencor (NASDAQ:XNCR) and MacroGenics (NASDAQ:MGNX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, media sentiment, valuation and risk.

MacroGenics has a net margin of -44.79% compared to Xencor's net margin of -177.10%. Xencor's return on equity of -28.77% beat MacroGenics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xencor	-177.10%	-28.77%	-20.52%
MacroGenics	-44.79%	-147.80%	-28.40%

MacroGenics has higher revenue and earnings than Xencor. Xencor is trading at a lower price-to-earnings ratio than MacroGenics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xencor	$125.58M	8.83	-$91.92M	-$2.29	N/A
MacroGenics	$149.50M	1.82	-$74.62M	-$1.10	N/A

In the previous week, Xencor had 2 more articles in the media than MacroGenics. MarketBeat recorded 6 mentions for Xencor and 4 mentions for MacroGenics. MacroGenics' average media sentiment score of 0.91 beat Xencor's score of 0.66 indicating that MacroGenics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xencor	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MacroGenics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Xencor has a beta of 0.86, suggesting that its stock price is 14% less volatile than the broader market. Comparatively, MacroGenics has a beta of 1.18, suggesting that its stock price is 18% more volatile than the broader market.

Xencor presently has a consensus price target of $24.25, suggesting a potential upside of 62.21%. MacroGenics has a consensus price target of $5.50, suggesting a potential upside of 28.21%. Given Xencor's stronger consensus rating and higher possible upside, equities research analysts plainly believe Xencor is more favorable than MacroGenics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xencor	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50
MacroGenics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

96.9% of MacroGenics shares are owned by institutional investors. 5.1% of Xencor shares are owned by insiders. Comparatively, 13.6% of MacroGenics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

MacroGenics beats Xencor on 9 of the 16 factors compared between the two stocks.

How does MacroGenics compare to Sana Biotechnology?

MacroGenics (NASDAQ:MGNX) and Sana Biotechnology (NASDAQ:SANA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation, analyst recommendations and media sentiment.

MacroGenics currently has a consensus price target of $5.50, suggesting a potential upside of 28.21%. Sana Biotechnology has a consensus price target of $9.50, suggesting a potential upside of 166.11%. Given Sana Biotechnology's stronger consensus rating and higher probable upside, analysts plainly believe Sana Biotechnology is more favorable than MacroGenics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MacroGenics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

MacroGenics has higher revenue and earnings than Sana Biotechnology. MacroGenics is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MacroGenics	$149.50M	1.82	-$74.62M	-$1.10	N/A
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.93	N/A

Sana Biotechnology has a net margin of 0.00% compared to MacroGenics' net margin of -44.79%. Sana Biotechnology's return on equity of -108.01% beat MacroGenics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MacroGenics	-44.79%	-147.80%	-28.40%
Sana Biotechnology	N/A	-108.01%	-40.68%

MacroGenics has a beta of 1.18, indicating that its stock price is 18% more volatile than the broader market. Comparatively, Sana Biotechnology has a beta of 2.13, indicating that its stock price is 113% more volatile than the broader market.

96.9% of MacroGenics shares are held by institutional investors. Comparatively, 88.2% of Sana Biotechnology shares are held by institutional investors. 13.6% of MacroGenics shares are held by company insiders. Comparatively, 25.4% of Sana Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, MacroGenics and MacroGenics both had 4 articles in the media. MacroGenics' average media sentiment score of 0.91 beat Sana Biotechnology's score of 0.47 indicating that MacroGenics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MacroGenics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sana Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Sana Biotechnology beats MacroGenics on 9 of the 14 factors compared between the two stocks.

Get MacroGenics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MGNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MGNX vs. The Competition

Export

Metric	MacroGenics	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$286.03M	$8.67B	$6.86B	$12.44B
Dividend Yield	N/A	2.55%	2.68%	8.42%
P/E Ratio	-3.90	15.65	27.01	24.38
Price / Sales	1.82	6.52	521.33	91.92
Price / Cash	N/A	18.09	48.59	59.36
Price / Book	4.88	3.56	10.95	6.33
Net Income	-$74.62M	$228.19M	$3.59B	$331.02M
7 Day Performance	-7.94%	-1.41%	-1.45%	-0.33%
1 Month Performance	3.87%	-2.08%	2.78%	-1.29%
1 Year Performance	187.92%	2.26%	28.53%	21.30%

MacroGenics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MGNX MacroGenics	2.6023 of 5 stars	$4.29 -4.7%	$5.50 +28.2%	+171.5%	$286.03M	$149.50M	N/A	430
CALT Calliditas Therapeutics AB (publ)	N/A	$40.00 flat	N/A	N/A	$1.19B	$1.60B	N/A	180
COLL Collegium Pharmaceutical	2.6178 of 5 stars	$36.44 -2.7%	$57.50 +57.8%	+6.7%	$1.18B	$780.57M	17.86	210	News Coverage Positive News
PURR Hyperliquid Strategies	2.401 of 5 stars	$8.18 -7.3%	$12.72 +55.5%	N/A	$1.18B	$1M	N/A	N/A
XNCR Xencor	2.2305 of 5 stars	$15.67 +5.2%	$24.25 +54.8%	+68.9%	$1.16B	$125.58M	N/A	280

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MGNX) was last updated on 7/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MacroGenics (MGNX) Competitors

MGNX vs. CALT, COLL, PURR, XNCR, and SANA

How does MacroGenics compare to Calliditas Therapeutics AB (publ)?

Summary

How does MacroGenics compare to Collegium Pharmaceutical?

Summary

How does MacroGenics compare to Hyperliquid Strategies?

Summary

How does MacroGenics compare to Xencor?

Summary

How does MacroGenics compare to Sana Biotechnology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MGNX vs. The Competition

MacroGenics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MacroGenics (MGNX) Competitors

MGNX vs. CALT, COLL, PURR, XNCR, and SANA

How does MacroGenics compare to Calliditas Therapeutics AB (publ)?

Which has more risk and volatility, MGNX or CALT?

Does the media refer more to MGNX or CALT?

Is MGNX or CALT more profitable?

Do insiders and institutionals believe in MGNX or CALT?

Do analysts rate MGNX or CALT?

Which has stronger valuation and earnings, MGNX or CALT?

Summary

How does MacroGenics compare to Collegium Pharmaceutical?

Do insiders & institutionals hold more shares of COLL or MGNX?

Is COLL or MGNX more profitable?

Which has more risk & volatility, COLL or MGNX?

Do analysts prefer COLL or MGNX?

Which has stronger valuation and earnings, COLL or MGNX?

Does the media favor COLL or MGNX?

Summary

How does MacroGenics compare to Hyperliquid Strategies?

Does the media refer more to MGNX or PURR?

Do institutionals & insiders hold more shares of MGNX or PURR?

Is MGNX or PURR more profitable?

Which has stronger earnings & valuation, MGNX or PURR?

Do analysts rate MGNX or PURR?

Which has more risk and volatility, MGNX or PURR?

Summary

How does MacroGenics compare to Xencor?

Is XNCR or MGNX more profitable?

Which has better earnings & valuation, XNCR or MGNX?

Does the media prefer XNCR or MGNX?

Which has more volatility and risk, XNCR or MGNX?

Do analysts recommend XNCR or MGNX?

Do institutionals and insiders hold more shares of XNCR or MGNX?

Summary

How does MacroGenics compare to Sana Biotechnology?

Do analysts recommend MGNX or SANA?

Which has better earnings and valuation, MGNX or SANA?

Is MGNX or SANA more profitable?

Which has more risk and volatility, MGNX or SANA?

Do insiders & institutionals hold more shares of MGNX or SANA?

Does the media refer more to MGNX or SANA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MGNX vs. The Competition

MacroGenics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools